Spectrila® (asparaginase) by Medac received EU-wide approval for the treatment of ALL
The pharmaceutical company Medac was granted a marketing authorisation by the European Commission for Spectrila® (asparaginase), to be used as a part of an antineoplastic combination therapy to treat children and adults with acute lymphoblastic leukaemia
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Medical Devices Oncology Patient care acute lymphoblastic leukaemia ALL amino acid antineoplastic combination therapy asparaginase enzyme Latest News Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Children | Drugs & Pharmacology | Leukemia | Marketing | Medical Devices